



MGFA Scientific Session

The Myasthenia Gravis Foundation of America (MGFA) Medical/Scientific Advisory Board presents a scientific session highlighting research in the field of MG and myasthenic disorders. This session is the premier annual event in the US, and around the world, related to the pathogenesis, immunology, diagnosis, and treatment of MG and related disorders of the NMJ. Included in the program will be leaders in MG research from the scientific and clinical areas.

All times are in Eastern Time.

10:00 am: *Exhibit Hall and Poster Hall opens*

11:00 am: *Welcome*

Samantha Masterson, CEO, MGFA

11:05 am: *Introduction of Keynote Speaker*

Srikanth Muppidi, MD

11:10 am: *A Crisis in US Drug Pricing: Consequences for Neuromuscular Physicians, Their Patients and Society*

A. Gordon Smith, MD FAAN

11:40 am: *Q & A*

11:55 am: *Introduction: Patient and Physician Perspectives on MG Care*

Ali Habib, MD

12:00 pm: *Real-World Patient-Reported Impact of Myasthenia Gravis: Initial Data from the MyRealWorld MG Study*

Francesco Saccà, MD

12:15 pm: *Reduced Fatigue as a Treatment Goal in Generalized Myasthenia Gravis: Patient and Physician Perspectives in the US & Myasthenia Gravis from the Patient's Perspective: Reducing Fatigue is a Priority*
Carolina Barnett Tapia, MD, PhD

12:25 pm: *Perspectives on Myasthenia Gravis: The Quality of Life and Productivity of Caregivers & Perspectives on Myasthenia Gravis: The Impact on Quality of Life, Productivity and Employment in the United States*

Milada Mahic, PhD

12:35 pm: *Diagnostic Delay in Myasthenia Gravis*
Andres De Leon, MD

12:40 pm: *What Does it Mean to be Better? Minimal Manifestations, MG-ADL, AND QMG*
Henry Kaminski, MD

12:50 pm: *Q & A Panel*

1:05 pm: *Break – visit the Exhibits and Posters*

1:15 pm: *Introduction: MG Biomarkers*
Shruti Raja, MD

1:20 pm: *Discovery Phase Study for Treatment-Predictive Biomarkers of MG*
Patricia Sikorski, PhD

1:35 pm: *Development of A Cell-Based Assay for Measuring Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients with Myasthenia Gravis*
Kevin O'Connor, PhD

1:50 pm: *To Measure MuSK Abs in AchR Ab Negative Sera: RIPA Is More Specific, And SPR Is More Sensitive*
Hans Frykman, MD, PhD, FRCPC

1:55 pm: *Pathogenic Th17 Cells in Autoimmune Myasthenia Gravis Exhibit a Pro-Inflammatory Transcriptomic Signature That Promote Disease Pathogenesis*
Kevin Li, PhD

2:00 pm: *Q & A Panel*

2:15 pm: *Introduction: MG Clinical Trials*
Srikanth Muppidi, MD

2:20 pm: *Efgartigimod Treatment of Patients with Generalized Myasthenia Gravis Demonstrates Consistent Improvements Across All Muscle Subgroups and Regardless of Background Immunosuppressive Therapy*
Chafic Karam, MD

2:35 pm: *Effect of Efgartigimod, a Neonatal FC Receptor Blocker, on Humoral Vaccine Responses in Autoimmune Patients*
Jeffrey Guptill, MD

2:50 pm: *Cumulative Burden of Refractory Generalized Myasthenia Gravis and the Therapeutic Effects of Eculizumab: An Exploratory Analysis*
Pushpa Narayanaswami, MD, FAAN

2:55 pm: *Efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG study*

Tuan Vu, MD

3:00 pm: *Q & A Panel*

3:15 pm: *Break – visit the Exhibits and Posters*

3:30 pm: *Introduction: Lessons from Clinical Practice*

Ali Habib, MD

3:35 pm: *Analysis of The Duke Myasthenia Gravis (MG) Clinic Registry: Thymectomy*

Shruti Raja, MD

3:50 pm: *Real-World Use of Eculizumab in Generalized Myasthenia Gravis in the US: Results from a Pilot Retrospective Chart-Review Study*

Sri Muppidi, MD

3:55 pm: *Safety and Tolerability of Sars-Cov-2 Vaccination in Patients with Myasthenia Gravis: A Single Center Experience*

Melanie Meton, RN

4:00 pm: *The Duke Myasthenia Gravis Clinic Registry: Factors Predicting Generalization of Ocular MG*

Donald Sanders, MD

4:05 pm: *Q & A Panel*

4:15 pm: *Closing and thank you.*

Samantha Masterson, CEO, MGFA

Please note that slight changes to the program may occur due to speaker availability.